Effects of Intensive Glucose Lowering in Type 2 Diabetes

[1]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[2]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[3]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[4]  Silvio E. Inzucchi,et al.  Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.

[5]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[6]  H. Gerstein,et al.  Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[7]  Michael E. Miller,et al.  Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[8]  D. Goff,et al.  Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.

[9]  Lawrence A Leiter,et al.  Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[10]  W. Cushman,et al.  Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[11]  J. Williamson,et al.  Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[12]  J. Tu,et al.  Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study , 2006, The Lancet.

[13]  M. Magee,et al.  Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. , 2006, The American journal of cardiology.

[14]  S. Yusuf,et al.  The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis , 2005, Diabetologia.

[15]  J. Wyatt,et al.  Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. , 2005, Journal of diabetes and its complications.

[16]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[17]  D. Reda,et al.  Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. , 2003, Journal of diabetes and its complications.

[18]  L. Melton,et al.  Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. , 2003, Archives of internal medicine.

[19]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[20]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[21]  F. Nuttall,et al.  Cardiovascular Events and Correlates in the Veterans Affairs Diabetes Feasibility Trial Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes , 1997 .

[22]  S. Yusuf,et al.  Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). , 2008, American heart journal.

[23]  M. Laakso,et al.  Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary , 2007 .

[24]  Advance Management Committee.  Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation , 2001, Diabetologia.

[25]  S. Genuth.  Exogenous Insulin Administration and Cardiovascular Risk in Non-Insulin-dependent and Insulin-dependent Diabetes Mellitus , 1996, Annals of Internal Medicine.

[26]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.